MetalloBio is an antimicrobials development company working on completely novel types of antibacterial compounds. Series 1 compounds are candidate antibiotics for complicated and difficult-to-treat infections. Series 2 compounds are the basis of new coatings for medical devices such as catheters and orthopaedic implants.
MetalloBio antibacterials are fast-acting bactericides which work through novel modes of action. An advanced Series 1 candidate, KLS-116, has at least two killing activities and elicits minimal resistance. Series 2 compounds, with a different bactericidal function, function in coatings with tunable antibacterial properties. MetalloBio compounds can also penetrate and disrupt the biofilms seen in many untreatable infections.
MetalloBio is driven fundamentally to change the nature of antibiotics and the treatment of infections.
Our radically different antimicrobials have molecular architectures based on inorganic chemistry.
Their modular design, built around an inert metal ion core provides a chemically robust platform that possesses the flexibility to produce many derivatives with targeted antimicrobial properties.
These water soluble compounds are thermostable up to 350°C and are active across a wide pH range (pH3-pH10) and against a broad spectrum of bacteria, including all WHO priority pathogens. Yet they display low toxicity to eukaryotic cells.
While the acronym "AMR" is being used by pharmaceutical and medical experts, what this really means for the rest of us is the arrival of untreatable infections. If we do not meet this challenge, medicine will be set back by more than a century. Without effective antibiotics, safe surgical procedures and the treatment of many diseases will become almost impossible.
To publicise this issue, and help kick-start the identification of the next wave of antimicrobials for healthcare, we are in regular dialogue with drug companies, investors, public bodies, medical charities, government organisations, patients and members of the lay public; so that together we can solve this urgent challenge to the global community.
From 1930 to 1962, more than 20 new types of antibiotics came to the market. In the last 50 years only 2 new classes have followed.
Current antibiotics are increasingly ineffective in treating infections as, catalysed by overuse and poor treatment management, antimicrobial resistance to these treatments inexorably emerges.
Many major pharmaceutical companies abandoned research into new antibiotics decades ago for commercial and clinical reasons. With the current threat of potentially untreatable infections, the identification of new therapeutics to overcome antimicrobial resistance (AMR), is not only timely but urgently needed.
MetalloBio is fundraising right now. We need investment to test a range of our candidate antibiotics, all analogues of our most advanced compound KLS-116, to select the best to take forward into clinical trials. This will require detailed investigations to understand exactly how our candidate antibiotics work on a range of different clinical pathogens. The data generated will be invaluable in determining which types of infection our compounds will be most effective against and could indicate which other antibiotics can be used with ours to improve the treatment of yet more infections.
INvest NOW
Keep up with the latest developments at MetalloBio in our News section. Here, you will find updates on our cutting-edge research, breakthroughs in the fight against untreatable infections, and important company milestones. Stay informed about how we are making a global impact and contributing to the the future of healthcare through innovative solutions.
View More News>>Stay connected with MetalloBio as we participate in key industry events and conferences around the globe. These events are crucial platforms for us to share our groundbreaking research, connect with potential partners, and engage with the global community on the urgent issue of antimicrobial resistance (AMR). Explore the list of upcoming events where you can meet our team, learn about our latest innovations, and discover how we are leading the fight against untreatable infections.
See More Events >>